Investment firm Martin Currie Ltd has a $35.12 million stake in ResMed Inc. (RMD). ResMed's July 2026 options have become available and the company's margin expansion is affecting its role as a defensive portfolio anchor. ResMed's strong Q1 results and new industry trends may lead to action by investors. With strong start to the year, share values have retracted, prompting question whether it is time to buy. Commercial resilience of ResMed during a recession boosts its attractiveness for investment. Entropy Technologies LP and Vanguard Group Inc. have purchased ResMed shares. Notably, Q1 2026 Earnings highlights included strong revenue growth and strategic innovations. Creative Planning bought 1,765 shares. Wall Street projections are forthcoming ahead of its earnings announcement. New platform launch and investments in U.S operations further the narrative. Several asset management companies including Nomura, and SG Americas Securities LLC, have increased their holdings in ResMed. Baird and Mizuho maintain ResMed's Outperform recommendation implying healthy stock prospects. Institutional owners hold 74% of ResMed. Furthermore, multiple earnings and revenue beats support analysts’ bullish outlook for ResMed. However, a potential U.S. Probe into medical device imports could impact the bull case for ResMed.
Resmed RMD News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 22 Nov 2025 12:59:13 GMT - Rating 7 - Innovation 8 - Information 5 - Rumor 1
